ProKidney Corp. (NASDAQ:PROK - Get Free Report)'s share price was down 2.7% on Tuesday . The company traded as low as $1.37 and last traded at $1.46. Approximately 395,546 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 414,379 shares. The stock had previously closed at $1.50.
ProKidney Trading Down 2.0 %
The company has a market capitalization of $358.74 million, a PE ratio of -2.24 and a beta of 1.31. The stock's 50-day moving average is $1.63 and its two-hundred day moving average is $1.87.
Institutional Trading of ProKidney
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in ProKidney in the 3rd quarter worth about $41,000. Intech Investment Management LLC bought a new position in ProKidney in the 3rd quarter worth about $46,000. ProShare Advisors LLC grew its stake in ProKidney by 57.3% in the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock worth $52,000 after acquiring an additional 11,250 shares in the last quarter. Sei Investments Co. bought a new position in ProKidney in the 4th quarter worth about $69,000. Finally, The Manufacturers Life Insurance Company grew its stake in ProKidney by 54.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company's stock worth $73,000 after acquiring an additional 13,415 shares in the last quarter. 51.59% of the stock is owned by hedge funds and other institutional investors.
ProKidney Company Profile
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Articles
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
